CN117413932A - 一种保肝组合物及其相关应用 - Google Patents
一种保肝组合物及其相关应用 Download PDFInfo
- Publication number
- CN117413932A CN117413932A CN202311633967.9A CN202311633967A CN117413932A CN 117413932 A CN117413932 A CN 117413932A CN 202311633967 A CN202311633967 A CN 202311633967A CN 117413932 A CN117413932 A CN 117413932A
- Authority
- CN
- China
- Prior art keywords
- composition
- inositol
- capsule
- parts
- liver
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 41
- 210000004185 liver Anatomy 0.000 title claims description 5
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims abstract description 21
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims abstract description 20
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims abstract description 12
- 229960000367 inositol Drugs 0.000 claims abstract description 12
- 238000002360 preparation method Methods 0.000 claims abstract description 12
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims abstract description 11
- 229960001231 choline Drugs 0.000 claims abstract description 11
- 108010024636 Glutathione Proteins 0.000 claims abstract description 10
- 239000000284 extract Substances 0.000 claims abstract description 10
- CDAISMWEOUEBRE-LKPKBOIGSA-N 1D-chiro-inositol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O CDAISMWEOUEBRE-LKPKBOIGSA-N 0.000 claims abstract description 9
- 229960003180 glutathione Drugs 0.000 claims abstract description 9
- 241000320380 Silybum Species 0.000 claims abstract description 8
- 235000010841 Silybum marianum Nutrition 0.000 claims abstract description 8
- 239000002775 capsule Substances 0.000 claims description 24
- 241000196324 Embryophyta Species 0.000 claims description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 6
- 208000006454 hepatitis Diseases 0.000 claims description 6
- 240000008042 Zea mays Species 0.000 claims description 5
- 239000008187 granular material Substances 0.000 claims description 5
- 239000002552 dosage form Substances 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 4
- 230000003908 liver function Effects 0.000 claims description 4
- 206010008909 Chronic Hepatitis Diseases 0.000 claims description 3
- 208000004930 Fatty Liver Diseases 0.000 claims description 3
- 206010016654 Fibrosis Diseases 0.000 claims description 3
- 206010019708 Hepatic steatosis Diseases 0.000 claims description 3
- 206010019799 Hepatitis viral Diseases 0.000 claims description 3
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims description 3
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims description 3
- 230000001154 acute effect Effects 0.000 claims description 3
- 235000012000 cholesterol Nutrition 0.000 claims description 3
- 230000007882 cirrhosis Effects 0.000 claims description 3
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 3
- 235000005822 corn Nutrition 0.000 claims description 3
- 208000010706 fatty liver disease Diseases 0.000 claims description 3
- 231100000240 steatosis hepatitis Toxicity 0.000 claims description 3
- 201000001862 viral hepatitis Diseases 0.000 claims description 3
- 230000002633 protecting effect Effects 0.000 claims description 2
- 208000019423 liver disease Diseases 0.000 abstract description 3
- 208000024891 symptom Diseases 0.000 abstract 1
- 239000000463 material Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 4
- SEBFKMXJBCUCAI-UHFFFAOYSA-N NSC 227190 Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-UHFFFAOYSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- SEBFKMXJBCUCAI-HKTJVKLFSA-N silibinin Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 description 3
- 229960004245 silymarin Drugs 0.000 description 3
- 235000017700 silymarin Nutrition 0.000 description 3
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000007493 shaping process Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000011158 quantitative evaluation Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000012502 risk assessment Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/30—Encapsulation of particles, e.g. foodstuff additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Botany (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明属于保健品制备领域,具体涉及一种保肝组合物及其相关应用。该组合物由奶蓟草提取物、谷胱甘肽、肌肉肌醇、D‑手性肌醇和胆碱组成。上述组分能够有效改善肝部疾病患者的症状,明显降低肝脏疾病风险值。
Description
技术领域
本发明属于保健品制备领域,具体涉及一种保肝组合物及其相关应用。
背景技术
现有技术提供的保肝保健品普存在成份过于复杂的缺陷,由于配伍繁杂使得保健效果并不明确,更有甚者配方中含有大量的成分难以明确的植物或者是不利于大量摄入的化合物。同时为了保证保健品的长时间保存以及保持易于服用的口感,保健品中会夹杂有大量与保健功能无关的辅料,使得保健品与其宣传的效果出现名不副实的情况。如某市售保肝保健品,有效成分虽然只有四种,但是辅料多达九种。另外一些保健品的剂型也有选择不合理的问题,如冲剂虽然携带方便但是具有冲泡时难以控制温度,导致有效物质存在吸收方面的缺陷的问题,而且服用时还需要另外准备器具并不便于服用;一些片剂出于塑形目的需要额外添加塑形剂等无关辅料。
发明内容
本发明的目的在于提供一种保肝组合物及其相关应用。本发明提供的保肝组合物的组分经过临床医师在免疫治疗实践中的经验,反复实验和验证挑选得到的,配比简单、效果显著,无任何辅助添加。
本发明提供了一种保肝组合物,所述组合物由以下组分组成:奶蓟草提取物、谷胱甘肽、肌肉肌醇、D-手性肌醇和胆碱。
在本发明中,所述组合物由以下质量份的组分组成;奶蓟草提取物475~525份、谷胱甘肽380~420份、肌肉肌醇380~420份、D-手性肌醇9.5~10.5份和胆碱237.5~262.5份。
在本发明中,所述组合物的剂型包括胶囊剂。
在本发明中,当所述组合物的剂型为胶囊剂时,所述胶囊剂中的胶囊为玉米制的植物胶囊。
在本发明中,当所述组合物的剂型为胶囊剂时,每个胶囊含有组合物0.3~0.4g。
在本发明中,当所述组合物的剂型为胶囊剂时,服用组合物的频率为一日两次,每次二粒。
本发明还提供了上述组合物在制备制备具有保护肝脏功能功效的制剂中的应用。
本发明还提供了上述组合物在制备具有提高代谢代谢脂肪和胆固醇功效的制剂中的应用。
本发明还提供了上述组合物在制备具有改善病毒性肝炎患者、急慢性肝炎患者、肝硬化患者、高脂肪肝患者肝功能的制剂中的应用。
本发明所使用原辅料为药食同源,全部为自然提取物及自然提取物纯化的单质,采用的植物胶囊壳为纯玉米制品。有效成分仅由奶蓟草提取物、谷胱甘肽、肌肉肌醇、D-手性肌醇和胆碱这五种组成,辅料只选择了植物胶囊,除此之外再无其他辅助材料的添加。上述有效成分及所用辅料在安全用量下无毒副作用。而且各成分之间经过实验验证均无不良化合反应。
本发明提供的组合物主要用于病毒性肝炎、急慢性肝炎、肝硬化、高脂肪肝的患者。肌醇和胆碱结合可形成卵磷脂等,具有代谢脂肪、胆固醇、预防动脉硬化的营养代谢性疾病和心血管疾病。
具体实施方式
在本发明中,水飞蓟素的购买信息如下(下列信息有做规避处理,如需要进一步查证相关信息,可以联系发明人获取具体信息):
产品名称:水飞蓟素(Silymarin);产品编号:S0292;品牌:Sigma1.2;CAS No.:65666-07-1;制造商或供应商名称:Sigma-Aldrich(Shanghai)TradingCo.Ltd.509Renqing RoadZhangjiang High Tech East Park,PudongSHANGHAI201201SHANGHAICHINA西格玛奥德里奇(上海)贸易有限公司上海市浦东新区仁庆路509号默克股份两合公司64271达姆施塔特德国Phone:+49(0)61****-2440。
在本发明中,谷胱甘肽的购买信息如下:
产品名称:L-还原型谷胱甘肽Glutathione;产品编号:Y0000517;品牌:Sigma-Aldrich;CAS No.:70-18-8;制造商或供应商名称:Sigma-Aldrich(Shanghai)TradingCo.Ltd.509Renqing RoadZhangjiang High Tech East Park,PudongSHANGHAI201201SHANGHAICHINA西格玛奥德里奇(上海)贸易有限公司上海市浦东新区仁庆路509号默克股份两合公司64271达姆施塔特德国Phone:+49(0)61****-2440。
在本发明中,肌肉肌醇的的购买信息如下:
产品名称:肌醇myo-Inositol;产品编号:I5125;品牌:Sigma CAS No.:87-89-81.2;制造商或供应商名称:Sigma-Aldrich(Shanghai)Trading Co.Ltd.509Renqing RoadZhangjiang High Tech East Park,Pudong SHANGHAI 201201SHANGHAI CHINA西格玛奥德里奇(上海)贸易有限公司上海市浦东新区仁庆路509号默克股份两合公司64271达姆施塔特德国Phone:+49(0)61****-2440。
在本发明中,D-手性肌醇的的购买信息如下:
产品名称:手性肌醇D-chiro-Inositol;产品编号:74137;品牌:Sigma;CAS No.:643-12-91.2;制造商或供应商名称:Sigma-Aldrich(Shanghai)TradingCo.Ltd.509Renqing RoadZhangjiang High Tech East Park,PudongSHANGHAI201201SHANGHAICHINA西格玛奥德里奇(上海)贸易有限公司上海市浦东新区仁庆路509号默克股份两合公司64271达姆施塔特德国Phone:+49(0)61****-2440
在本发明中,胆碱的的购买信息如下:
产品名称:胆碱二柠檬酸盐Choline dihydrogencitrate salt;产品编号:C2004;品牌:Aldrich;CAS No.:77-91-81.2;制造商或供应商名称:Sigma-Aldrich(Shanghai)TradingCo.Ltd.509Renqing RoadZhangjiang High Tech East Park,PudongSHANGHAI201201SHANGHAICHINA西格玛奥德里奇(上海)贸易有限公司上海市浦东新区仁庆路509号默克股份两合公司64271达姆施塔特德国Phone:+49(0)61****-2440
在本发明中,植物胶囊的的购买信息如下:
品牌:仁心食匠;商品名称:植物玉米空胶囊壳;商品编号:10070882808832;货号:q3.15142753;产地:浙江金华。
实施例
制备保肝组合物胶囊剂使用的主辅料如下:奶蓟草提取物、谷胱甘肽、肌肉肌醇、D-手性肌醇、胆碱和植物胶囊(1号植物玉米空胶囊壳)。
奶蓟草提取物、谷胱甘肽、肌肉肌醇、D-手性肌醇和胆碱按照以下质量比:500﹕400﹕400﹕10﹕250混合后装入1号植物胶囊中,每个胶囊中含有390±20mg有效成分。
按照一日两次,每次2粒,30天用量,向志愿受试者(20岁至65岁)定量提供备试品。对35位被试者在基线日,采血10毫升做器官疾病风险评估。25名志愿者按要求完成试验,在服用结束一周内,再次采血10毫升做器官疾病风险量化评估。器官疾病风险量化评估委托杭州普罗亭医学检验试验有限公司(样本编号:161125006801至161125006870)。试验结果:其中21人肝脏疾病风险值有明显降低,约占84%。其中4人未有显著变化。初步摸底证明,该配方安全有效。
尽管上述实施例对本发明做出了详尽的描述,但它仅仅是本发明一部分实施例,而不是全部实施例,人们还可以根据本实施例在不经创造性前提下获得其他实施例,这些实施例都属于本发明保护范围。
Claims (9)
1.一种保肝组合物,其特征在于,所述组合物由以下组分组成:奶蓟草提取物、谷胱甘肽、肌肉肌醇、D-手性肌醇和胆碱。
2.根据权利要求1所述的组合物,其特征在于,所述组合物由以下质量份的组分组成;奶蓟草提取物475~525份、谷胱甘肽380~420份、肌肉肌醇380~420份、D-手性肌醇9.5~10.5份和胆碱237.5~262.5份。
3.根据权利要求1所述的组合物,其特征在于,所述组合物的剂型包括胶囊剂。
4.根据权利要求3所述的组合物,其特征在于,当所述组合物的剂型为胶囊剂时,所述胶囊剂中的胶囊为玉米制的植物胶囊。
5.根据权利要求3所述的组合物,其特征在于,当所述组合物的剂型为胶囊剂时,每个胶囊含有组合物0.3~0.4g。
6.根据权利要求3所述的组合物,其特征在于,当所述组合物的剂型为胶囊剂时,服用组合物的频率为一日两次,每次二粒。
7.权利要求1~6任一项所述的组合物在制备具有保护肝脏功能功效的制剂中的应用。
8.权利要求1~6任一项所述的组合物在制备具有提高代谢代谢脂肪和胆固醇功效的制剂中的应用。
9.权利要求1~6任一项所述的组合物在制备具有改善病毒性肝炎患者、急慢性肝炎患者、肝硬化患者、高脂肪肝患者肝功能的制剂中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311633967.9A CN117413932A (zh) | 2023-12-01 | 2023-12-01 | 一种保肝组合物及其相关应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311633967.9A CN117413932A (zh) | 2023-12-01 | 2023-12-01 | 一种保肝组合物及其相关应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117413932A true CN117413932A (zh) | 2024-01-19 |
Family
ID=89530321
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311633967.9A Pending CN117413932A (zh) | 2023-12-01 | 2023-12-01 | 一种保肝组合物及其相关应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117413932A (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105748448A (zh) * | 2016-02-29 | 2016-07-13 | 中国医学科学院医药生物技术研究所 | D手性肌醇在制备抗肝纤维化药物中的应用 |
WO2022070013A1 (en) * | 2020-09-29 | 2022-04-07 | Munisekhar Medasani | Bioactive compounds extraction from plant matters of silybum marianum and usage |
-
2023
- 2023-12-01 CN CN202311633967.9A patent/CN117413932A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105748448A (zh) * | 2016-02-29 | 2016-07-13 | 中国医学科学院医药生物技术研究所 | D手性肌醇在制备抗肝纤维化药物中的应用 |
WO2022070013A1 (en) * | 2020-09-29 | 2022-04-07 | Munisekhar Medasani | Bioactive compounds extraction from plant matters of silybum marianum and usage |
Non-Patent Citations (1)
Title |
---|
韩怡,等: "还原型谷胱甘肽联合水飞蓟宾治疗肝硬化的临床观察", 中国药房, no. 09, 31 December 2016 (2016-12-31) * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Pak et al. | Hepatotoxicity of herbal remedies: an emerging dilemma | |
WO2011037099A1 (ja) | ウコン抽出物とガジュツ抽出物とを含有する組成物 | |
US10894070B2 (en) | Drug compound for the control of blood glucose, blood lipids and weight | |
CN101548999A (zh) | 人参茎叶皂苷的制备及其抗肥胖的应用 | |
CN108497498A (zh) | 一种解酒护肝的功能性食品及其制备方法 | |
CN105902567B (zh) | 一种藏药成分七矿物灰的炮制方法 | |
JP5725638B2 (ja) | 体熱産生促進剤 | |
CN117413932A (zh) | 一种保肝组合物及其相关应用 | |
McKennon | Non-pharmaceutical intervention options for type 2 diabetes: complementary health approaches and integrative health (including natural products and mind/body practices) | |
CN102823688A (zh) | 蓝莓叶保健茶、保健胶囊及其制备方法 | |
Hussain et al. | Comparative in vitro analysis of anti-diabetic activity of Indo-Pak black cardamom (Amomum subulatum Roxb.) and Chinese black cardamom (Amomum tsao-ko Crevost et Lemaire) | |
JP5305500B2 (ja) | リパーゼ阻害剤及びそれを含有する組成物 | |
US20180169071A1 (en) | Nutritional supplement composition | |
CN1301557A (zh) | 玫瑰茄系列制品及其制备方法 | |
CN117414364A (zh) | 一种抗衰组合物及其相关应用 | |
CN1951471A (zh) | 一种蛇胆川贝液体胶囊及其制备方法 | |
CN105360787A (zh) | 一种保健食品及其制备方法 | |
CN108524548A (zh) | 一种夏枯草蜂蜜提取物及其应用 | |
JP2001321126A (ja) | 食品組成物 | |
CN108157969A (zh) | 一种补血养颜组合物及其制备方法 | |
CN106822762A (zh) | 一种质量稳定的风湿二十五味丸及其制备工艺 | |
JPH043365B2 (zh) | ||
Dugoua | Natural Health Products (NHPs) in Pregnancy and Lactation: A review of the landscape and blueprint for change | |
KR20010026440A (ko) | 숙취 제거 및 간장 보호를 위한 조성물 | |
Abirami | Preclinical study of Siddha Drug Bojana Kudori Mathirai for its Ovulation inducing, Hypolipidemic and Anti-oxidant activities |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |